Skip to main content

Table 2 Preoperative CRT versus surgery alone

From: Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials

Study and year Sample size Treatment approach Treatment schedule (CRT) 3 y or 5 y OS (CRT V. Surg)
Walsh, [27] 113 CRT-Surgery V. Surgery 40Gy/15f/15d 3y: 32% V. 6%
5-Fu (15 mg/kg/d)
5y: NM
Cisplatin (75 mg /m2)
Urba, [30] 100 CRT-Surgery V. Surgery 45Gy/15f/15d 3y: 30% V. 16%
Cisplatin (20 mg/m2/d)
5y: NM
5-Fu (300 mg/m2/d)
TROG, [31] 256 CRT-Surgery V. Surgery 35Gy/15f/3w 3y: 25.6% V. 24.1%
Cisplatin (80 mg/m2)
5y: 11.5% V. 9.6%
5-Fu (800 mg/m2)
CALGB9781, [28] 56 CRT-Surgery V. Surgery 50.4Gy/28f/28d 3y: NM
Cisplatin (100 mg/m2)
5y: 39% V. 16%
5-Fu (1000 mg/m2/d)
CROSS, [29] 366 CRT-Surgery V. Surgery 41.4Gy/23f 5f/w 3y: 39.6% V. 35.5%
Carboplatin (2 mg/ml/min)
5y: 13.4% V. 7.1%
Paclitaxel (50 mg/m2)
  1. Note: OS: overall survival; CRT: preoperative chemoradiation therapy; CT: preoperative chemotherapy; V: versus; Surg: surgery; 5-Fu: fluorouracil; NM: not mentioned.